Mississippi regulators are moving to revoke the license of cannabis testing lab Rapid Analytics after a seven-week investigation uncovered significant deviations from regulatory standards and approved procedures. This decision underscores the importance of compliance in the state’s medical cannabis landscape.
Retesting of Medical Cannabis Products
On December 21, the Mississippi State Department of Health (MSDH) placed a substantial number of medical cannabis products on hold for retesting, focusing on pesticides and mycotoxins. This administrative hold led to further retesting actions that began on January 3, with costs covered by the Mississippi Medical Cannabis Program (MMCP).
The initial hold was prompted by discrepancies found during an audit of Certificates of Analysis related to the original test results conducted by Rapid Analytics, based in Natchez, Mississippi. Following the completion of the investigation on February 9, the MSDH announced plans to revoke Rapid Analytics’ license, effective March 13.
The agency highlighted the critical role of medical cannabis testing in ensuring product safety for patients, stating, “Rapid Analytics’ disregard for regulatory compliance poses a threat to public health and welfare,” in a February 22 news release.
Appeal Process and Industry Impact
Rapid Analytics has 20 days to appeal the decision. According to the Natchez Democrat, the company’s owner, Mamie Henry, indicated that an appeal was filed on January 5. Initially cooperative with the investigation, Henry expressed a loss of confidence in the process, stating, “We no longer have faith in the investigation.”
This situation raises critical questions about compliance and accountability within Mississippi’s cannabis industry, an evolving sector that relies heavily on regulatory integrity.
